Structure of Ifetroban
CAS No.: 143443-90-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Ifetroban is a long-acting thromboxane A2 receptor antagonist, with antiplatelet activity.
Synonyms: BMS-180291
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 143443-90-7 |
Formula : | C25H32N2O5 |
M.W : | 440.53 |
SMILES Code : | O=C(O)CCC1=CC=CC=C1C[C@H]2[C@](O3)([H])CC[C@]3([H])[C@H]2C4=NC(C(NCCCCC)=O)=CO4 |
Synonyms : |
BMS-180291
|
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02216357 | - | Completed | - | - | |
NCT03340675 | Duchenne Muscular Dystrophy Ca... More >>rdiomyopathy Cardiomyopathy, Dilated Less << | Phase 2 | Not yet recruiting | December 2021 | - |
NCT02802228 | Portal Hypertension ... More >> Liver Cirrhosis Less << | Phase 2 | Completed | - | United States, Florida ... More >> Tampa General Medical Group Tampa, Florida, United States, 33606 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Ohio The Ohio State University Wexner Medical Center Columbus, Ohio, United States, 43210 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Commonwealth University Medical Center Richmond, Virginia, United States, 23114 Less << |
NCT03694249 | Anatomic Stage II Breast Cance... More >>r Anatomic Stage IIA Breast Cancer Anatomic Stage IIB Breast Cancer Anatomic Stage III Breast Cancer Anatomic Stage IIIA Breast Cancer Anatomic Stage IIIB Breast Cancer Anatomic Stage IIIC Breast Cancer Clinical Stage II Esophageal Adenocarcinoma Clinical Stage II Esophageal Squamous Cell Carcinoma Clinical Stage II Gastric Cancer Clinical Stage II Gastroesophageal Junction Adenocarcinoma Clinical Stage IIA Esophageal Adenocarcinoma Clinical Stage IIA Gastric Cancer Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma Clinical Stage IIB Esophageal Adenocarcinoma Clinical Stage IIB Gastric Cancer Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma Clinical Stage III Esophageal Adenocarcinoma Clinical Stage III Esophageal Squamous Cell Carcinoma Clinical Stage III Gastric Cancer Clinical Stage III Gastroesophageal Junction Adenocarcinoma Distal Esophagus Squamous Cell Carcinoma Esophageal Carcinoma Estrogen Receptor Negative HER2/Neu Negative Limited Stage Small Cell Lung Carcinoma Malignant Solid Neoplasm Non-Small Cell Lung Carcinoma Pancreatic Adenocarcinoma Pathologic Stage II Esophageal Adenocarcinoma Pathologic Stage II Esophageal Squamous Cell Carcinoma Pathologic Stage II Gastric Cancer Pathologic Stage II Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIA Esophageal Adenocarcinoma Pathologic Stage IIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIA Gastric Cancer Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIB Esophageal Adenocarcinoma Pathologic Stage IIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIB Gastric Cancer Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage III Esophageal Adenocarcinoma Pathologic Stage III Esophageal Squamous Cell Carcinoma Pathologic Stage III Gastric Cancer Pathologic Stage III Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIA Esophageal Adenocarcinoma Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIIA Gastric Cancer Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIB Esophageal Adenocarcinoma Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIIB Gastric Cancer Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIC Gastric Cancer Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage II Gastric Cancer Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage III Gastric Cancer Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma Progesterone Receptor Negative Prognostic Stage II Breast Cancer Prognostic Stage IIA Breast Cancer Prognostic Stage IIB Breast Cancer Prognostic Stage III Breast Cancer Prognostic Stage IIIA Breast Cancer Prognostic Stage IIIB Breast Cancer Prognostic Stage IIIC Breast Cancer Stage I Pancreatic Cancer Stage IA Pancreatic Cancer Stage IB Pancreatic Cancer Stage II Lung Cancer Stage II Pancreatic Cancer Stage IIA Lung Cancer Stage IIA Pancreatic Cancer Stage IIB Lung Cancer Stage IIB Pancreatic Cancer Stage III Lung Cancer Stage IIIA Lung Cancer Stage IIIB Lung Cancer Stage IIIC Lung Cancer Triple-Negative Breast Carcinoma Less << | Phase 2 | Not yet recruiting | January 2023 | United States, Tennessee ... More >> Vanderbilt-Ingram Cancer Center Not yet recruiting Nashville, Tennessee, United States, 37232 Contact: Vanderbilt-Ingram Service for Timely Access 800-811-8480 cip@vanderbilt.edu Principal Investigator: Ingrid Mayer, MD Less << |
NCT01436500 | Hepatorenal Syndrome | Phase 2 | Completed | - | United States, Arizona ... More >> Mayo Clinic - Arizona Phoenix, Arizona, United States, 85054 United States, California UCSD, Hillcrest Medical Center Hospital La Jolla, California, United States, 92093 UCSF (University of California-San Francisco) San Francisco, California, United States, 94143 United States, Georgia Emory University Hospital Atlanta, Georgia, United States, 30322 United States, Indiana Indiana University (Division of Gastroenterology/Hepatology) Indianapolis, Indiana, United States, 46202 United States, Michigan University of Michigan Hospital Ann Arbor, Michigan, United States, 48109 United States, New York NYU Langone Medical Center New York, New York, United States, 10016 United States, Ohio The Ohio State University Columbus, Ohio, United States, 43210 United States, Texas Baylor All Saints Medical Center Fort Worth, Texas, United States, 76104 United States, Utah University of Utah Health Sciences Center Salt Lake City, Utah, United States, 84132 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 India MIDAS Multispeciality Hospital PVT LTD Nagpur, Maharashtra, India, 440010 Less << |
NCT02216357 | Aspirin Exacerbated Respirator... More >>y Disease (AERD) Less << | Phase 2 | Completed | - | United States, California ... More >> Scripps Clinic San Diego, California, United States, 32130 United States, Kansas Kansas City Allergy and Asthma Associates, PA. Overland Park, Kansas, United States, 66210 United States, New York Allergy & Asthma Consultants of Rockland & Bergen West Nyack, New York, United States, 10994 Less << |
NCT03326063 | Nasal Polyps ... More >>Asthma, Aspirin-Induced Aspirin-exacerbated Respiratory Disease Aspirin-Sensitive Asthma With Nasal Polyps Less << | Phase 2 | Recruiting | February 2021 | United States, Massachusetts ... More >> Asthma Research Center, Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Meghan Le 617-732-8201 mle8@bwh.harvard.edu Less << |
NCT02682511 | Scleroderma, Diffuse ... More >> Scleroderma, Systemic Scleroderma, Limited Sclerosis, Progressive Systemic Skin Diseases Connective Tissue Diseases Pathologic Processes Autoimmune Diseases Less << | Phase 2 | Recruiting | February 2020 | United States, California ... More >> UCLA Recruiting Los Angeles, California, United States, 90095-1670 Contact: Nashla Barroso 310-825-9682 Principal Investigator: Suzanne Kafaja, MD United States, Florida New Life Medical Research Center, Inc. Recruiting Hialeah, Florida, United States, 33012 Contact: Barbara Diaz, BS 786-360-3750 diaz@newlifemedresearch.com Principal Investigator: Odalys P Frontela, MD United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21224 Contact: Gwen Leatherman, RN, MS, CCRP 410-550-8582 Principal Investigator: Laura Hummer, MD United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Kaitlin Schalago 617-724-2792 Contact: Ana Fernandez 617-724-2792 Principal Investigator: Flavia Castelino, MD United States, New York Hospital for Special Surgery Recruiting New York, New York, United States, 10021 Contact: Alexandra Morquette 212-774-7194 Principal Investigator: Jessica Gordon, MD United States, South Carolina Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29403 Contact: Kelley Kajdasz 843-792-5290 Principal Investigator: Richard Silver, MD United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37203 Contact: Rezzan Hekmat, MHS 615-875-8937 Principal Investigator: Evan Brittain, MD Less << |
NCT03028350 | Asthma, Aspirin-Induced | Phase 2 | Recruiting | December 2019 | United States, California ... More >> Scripps Clinic - Carmel Valley Recruiting San Diego, California, United States, 92130 Contact: Nancy Giovanetty 858-764-3023 Principal Investigator: Andrew White, MD Stanford University Medical Center Recruiting Stanford, California, United States, 94305 Contact: Aakanksha Rathor, MD 408-872-2257 Principal Investigator: Peter Hwang, MD United States, Florida The Research Center Recruiting Hialeah, Florida, United States, 33013 Contact: Laine Batista 305-603-8844 Contact: Damian Beltran-Garces (305) 603-8844 United States, Kansas Kansas City Allergy and Asthma Associates, PA Recruiting Overland Park, Kansas, United States, 66210 Contact: James B Sterner, MD 913-338-1610 Contact: Andrea Bennington, CCRC 913-338-1610 United States, New York Montefiore Medical Center Recruiting Bronx, New York, United States, 10461 Contact: Mydalyn Beronilla, MPH 929-263-3262 Principal Investigator: Elina Jerschow, MD United States, Ohio Clinical Research Trials , LLC Recruiting Canton, Ohio, United States, 44718 Contact: Nashat Gabrail, MD 330-492-3345 Contact: Hannah Crocker 330-492-3345 United States, Pennsylvania University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: John V Bosso, MD Contact: Laurel Doghramji, BSN 215-615-1643 United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Cindy Dorminy, MEd, LPN 615-936-8384 Principal Investigator: Rakesh Chandra, MD United States, Texas UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390-9035 Contact: Mary Martin 214-648-3626 Principal Investigator: David Khan, MD United States, Virginia University of Virginia Medical Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: B.J. Ferrebee Ghamandi, MHA 434-243-1558 Principal Investigator: Spencer Payne, MD Less << |
NCT01436500 | - | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.27mL 0.45mL 0.23mL |
11.35mL 2.27mL 1.13mL |
22.70mL 4.54mL 2.27mL |
Tags: Ifetroban | BMS-180291 | Prostaglandin Receptor | GPCR/G Protein | 143443-90-7
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL